DCOY · Decoy Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Arthur David J. Chief Executive Officer | ▲ Buy | Grant | 48,019 Shares held | 2/13/2023 | View profile |
| PIERCE FREDERICK II Chief Executive Officer | ▲ Buy | Grant | 34,844 Shares held | 8/31/2026 | View profile |
| Rosenblum Mark J Exec VP Finance, CFO | ▲ Buy | Grant | 11,363 Shares held | 8/31/2026 | View profile |
| Hibner Barbara Louise Chief Scientific Officer | ▲ Buy | Grant | 4,216 Shares held | 8/31/2026 | View profile |
| Marschel Peter Klaus Chief Business Officer | ▲ Buy | Grant | 3,900 Shares held | 8/31/2026 | View profile |
| HANISH ARNOLD C Director | ▲ Buy | Grant | 3,418 Shares held | 8/31/2026 | View profile |
| McVicar William K. Director | ▲ Buy | Grant | 3,002 Shares held | 8/31/2026 | View profile |
| Lieber Jonathan I Director | ▲ Buy | Grant | 2,002 Shares held | 8/31/2026 | View profile |
| Burleson Tess Director | ▲ Buy | Grant | 2,002 Shares held | 8/31/2026 | View profile |
| Lammers Paul Director | ▲ Buy | Grant | 2,001 Shares held | 8/31/2026 | View profile |
| Gauthier Patricia G. | ▲ Buy | Grant | 2,000 Shares held | 8/31/2026 | View profile |
| McCreedy Bruce J Jr. Director | ▲ Buy | Grant | 1,788 Shares held | 1/3/2023 | View profile |
Transaction History
| PIERCE FREDERICK II | ▲ Buy | Grant | 33,455 | $0 | 8/31/2026 |
| Marschel Peter Klaus | ▲ Buy | Grant | 3,900 | $0 | 8/31/2026 |
| McVicar William K. | ▲ Buy | Grant | 3,000 | $0 | 8/31/2026 |
| Lieber Jonathan I | ▲ Buy | Grant | 2,000 | $0 | 8/31/2026 |
| Gauthier Patricia G. | ▲ Buy | Grant | 2,000 | $0 | 8/31/2026 |
| Rosenblum Mark J | ▲ Buy | Grant | 9,682 | $0 | 8/31/2026 |
| HANISH ARNOLD C | ▲ Buy | Grant | 3,000 | $0 | 8/31/2026 |
| Lammers Paul | ▲ Buy | Grant | 2,000 | $0 | 8/31/2026 |
| Burleson Tess | ▲ Buy | Grant | 2,000 | $0 | 8/31/2026 |
| Hibner Barbara Louise | ▲ Buy | Grant | 4,216 | $0 | 8/31/2026 |
| HANISH ARNOLD C | ▼ Sell | Open Market | 15 | $10 | 12/30/2025 |
| HANISH ARNOLD C | ▼ Sell | Open Market | 12 | $8 | 12/30/2025 |
| HANISH ARNOLD C | ▲ Buy | Open Market | 5,000 | $4K | 11/20/2025 |
| Rosenblum Mark J | ▲ Buy | Open Market | 20,000 | $16K | 11/20/2025 |
| Rosenblum Mark J | ▲ Buy | Grant | 6,432 | $0 | 2/13/2023 |
| Arthur David J. | ▲ Buy | Grant | 14,300 | $0 | 2/13/2023 |
| Lieber Jonathan I | ▲ Buy | Grant | 1,440 | $0 | 1/3/2023 |
| McCreedy Bruce J Jr. | ▲ Buy | Grant | 1,440 | $0 | 1/3/2023 |
| HANISH ARNOLD C | ▲ Buy | Grant | 1,440 | $0 | 1/3/2023 |
| Lammers Paul | ▲ Buy | Grant | 1,440 | $0 | 1/3/2023 |
| Burleson Tess | ▲ Buy | Grant | 1,440 | $0 | 1/3/2023 |
| McVicar William K. | ▲ Buy | Grant | 1,440 | $0 | 1/3/2023 |
| Rosenblum Mark J | ▲ Buy | Grant | 8,000 | $0 | 1/3/2023 |
| Arthur David J. | ▲ Buy | Grant | 20,000 | $0 | 1/3/2023 |
| Arthur David J. | ▲ Buy | Grant | 10,000 | $17K | 11/3/2022 |
| Rosenblum Mark J | ▲ Buy | Grant | 7,314 | $13K | 11/3/2022 |
| Lieber Jonathan I | ▲ Buy | Open Market | 37,500 | $7K | 6/7/2022 |
| Burleson Tess | ▲ Buy | Open Market | 27,700 | $5K | 6/7/2022 |
| McVicar William K. | ▲ Buy | Open Market | 26,553 | $5K | 6/6/2022 |
| HANISH ARNOLD C | ▲ Buy | Open Market | 28,000 | $5K | 6/3/2022 |
| Rosenblum Mark J | ▲ Buy | Open Market | 28,000 | $5K | 5/31/2022 |
| Arthur David J. | ▲ Buy | Open Market | 3,400 | $612 | 5/26/2022 |
| Arthur David J. | ▲ Buy | Open Market | 18,600 | $3K | 5/26/2022 |
| Arthur David J. | ▲ Buy | Open Market | 708 | $127 | 5/26/2022 |
| Arthur David J. | ▲ Buy | Open Market | 10,392 | $2K | 5/26/2022 |
| Arthur David J. | ▲ Buy | Open Market | 10,800 | $2K | 5/26/2022 |
| Rosenblum Mark J | ▲ Buy | Grant | 10,000 | $2K | 5/3/2022 |
| Arthur David J. | ▲ Buy | Grant | 10,000 | $2K | 5/3/2022 |
| Rosenblum Mark J | ▲ Buy | Open Market | 76,246 | $30K | 3/3/2022 |
| Arthur David J. | ▲ Buy | Open Market | 139,488 | $55K | 3/3/2022 |
| Rosenblum Mark J | ▲ Buy | Grant | 7,787 | $6K | 11/3/2021 |
| Arthur David J. | ▲ Buy | Grant | 7,939 | $6K | 11/3/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
DCOY Reports Preclinical Data for Once-Weekly Dosing
Decoy Therapeutics released preclinical data supporting a once-weekly intranasal dosing schedule for its DCOY-CoV program. The company is also scheduled to present at The Small Cap Showcase investor conference. These updates provide context for the stock's current trading levels, which sit near significant support.
DCOY Reports Preclinical Data for Once-Weekly Dosing. Decoy Therapeutics released preclinical data supporting a once-weekly intranasal dosing schedule for its DCOY-CoV program. The company is also scheduled to present at The Small Cap Showcase investor conference. These updates provide context for the stock's current trading levels, which sit near significant support.